Phase I clinical trial, Gleevec have kept CML patient alive for 17 years

Diagnosed with Chronic Myeloid Leukemia (CML), Mel Mann was given three years to live. That was more than 20 years ago. In August 1998, Mel was one of 20 patients that started the Phase I clinical trial for the drug STI571, now known as Gleevec. The drug was approved by the FDA in 2001 and Mel is still taking the drug today, making him MD Anderson’s longest living Gleevec patient. Read Mel’s story here: